 |
Case Report
Multimodal imaging in a case of acute erdafitinib-induced maculopathy
1 Specialty Retina Center, 2001 W Sample Rd #320, Deerfield Beach, FL, USA
2 Advanced Research Center, 2001 W Sample Rd #318, Deerfield Beach, FL 33064, USA
3 Department of Ophthalmology, Broward Health, 201 East Sample Road, Deerfield Beach, FL 33064, USA
4 The Ocular Immunology and Uveitis Foundation, 1440 Main Street #201, Waltham, MA 02451, USA
Address correspondence to:
Arash Maleki
MD, 2001 W Sample Rd, Suite 320, Deerfield Beach, FL 33064,
USA
Message to Corresponding Author
Article ID: 100051Z17NH2026
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Hallman N, Tsai JJ, Bawcombe D, Seith HB, Maleki A, Gupta S. Multimodal imaging in a case of acute erdafitinib-induced maculopathy. J Case Rep Images Opthalmol 2026;9(1):6–10.ABSTRACT
Introduction: To analyze multimodal imaging findings in a patient with erdafitinib-induced maculopathy.
Case Report: An 80-year-old male presented to our retina clinic with decreased vision in his left eye that began two weeks prior to his most recent visit. His past ocular history included epiretinal membranes in both eyes. He had been diagnosed with bladder cancer and had been undergoing aggressive chemotherapy, which was discontinued two months prior to this visit due to serious adverse effects. One month before the most recent visit, his oncologist had initiated treatment with erdafitinib. His best corrected visual acuity was 20/50 in the right eye and 20/100 in the left eye. Fundus examination revealed macular pucker, mild diabetic retinopathy, and mild hypertensive retinopathy in both eyes. Optical coherence tomography imaging of the macula showed new onset subretinal fluid in both eyes. Fluorescein angiography and indocyanine green angiography of the retina and choroid did not show any abnormalities explaining the subretinal fluid.
Conclusion: Erdafitinib can cause toxic maculopathy with subretinal fluid on optical coherence tomography of the retina with no abnormalities on fluorescein angiography and indocyanine green angiography.
Keywords: Erdafitinib, Fibroblast growth factor receptors, Subretinal fluid, Toxic maculopathy
SUPPORTING INFORMATION
Acknowledgments
Statement of Ethics: Ethics approval was not required by local guidelines or the North Broward Hospital Institutional Review Board.
Author ContributionsNicholas Hallman - Substantial contributions to conception and design, Acquisition of data, Revising it critically for important intellectual content, Final approval of the version to be published
Joby J Tsai - Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Drew Bawcombe - Interpretation of data, Drafting the article, Final approval of the version to be published
Heather B Seith - Interpretation of data, Drafting the article, Final approval of the version to be published
Arash Maleki - Substantial contributions to conception and design, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Shailesh Gupta - Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2026 Nicholas Hallman et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
